Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.
Therapies for MDS With Transfusion-Dependent Anemia
Andrew M. Brunner, MD, discusses the most notable outcomes of the phase 2/3 IMerge trial of imetelstat in patients with low-risk myelodysplastic syndrome.
Andrew M. Brunner, MD, discusses challenges and progress in identifying treatment for patients with transfusion-dependent myelodysplastic syndromes.
Amer Zeidan, MBBS, discusses common adverse events and toxicity management for imetelstat in patients with myelodysplastic syndromes.
Andrew M. Brunner, MD, discusses the mechanism of action of telomerase inhibitors as treatment for anemia related to myelodysplastic syndrome.
Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
Abdulraheem Yacoub, MD, discusses imetelstat as a newer and exciting option for patients with myelodysplastic syndromes.
Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
Mikkael A. Sekeres MD, MS, discusses transfusion independence rates with imetelstat in patients with low- to intermediate-1 risk myelodysplastic syndromes.
Mikkael A. Sekeres MD, MS, further discussed the approval of imetelstat for the treatment of patients with low- to intermediate-1 risk myelodysplastic syndromes.